These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27980429)

  • 1. Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication.
    Bonafede MM; Curtis JR; McMorrow D; Mahajan P; Chen CI
    Clinicoecon Outcomes Res; 2016; 8():707-715. PubMed ID: 27980429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
    Chastek B; Becker LK; Chen CI; Mahajan P; Curtis JR
    J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
    Wei W; Knapp K; Wang L; Chen CI; Craig GL; Ferguson K; Schwartzman S
    Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy.
    Bonafede MMK; McMorrow D; Proudfoot C; Shinde S; Kuznik A; Chen CI
    Am Health Drug Benefits; 2018 Jun; 11(4):192-202. PubMed ID: 30464787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
    Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
    J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-TNF inhibitor switchers versus TNF inhibitor cyclers from multicentre rheumatoid arthritis ultrasonography prospective cohort in Japan.
    Endo Y; Kawashiri SY; Morimoto S; Nishino A; Okamoto M; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Tada Y; Kawakami A
    Immunol Med; 2020 Sep; 43(3):115-120. PubMed ID: 32393150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
    Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
    Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
    Shahabi A; Shafrin J; Zhao L; Green S; Curtice T; Marshall A; Paul D
    J Med Econ; 2019 Apr; 22(4):350-358. PubMed ID: 30653389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.
    Lequerré T; Farran É; Ménard JF; Kozyreff-Meurice M; Vandhuick T; Tharasse C; Pouplin S; Daragon A; Le Loët X; Varin R; Vittecoq O
    Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M; Kaneko Y; Kondo H; Takeuchi T
    Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan.
    Sullivan E; Kershaw J; Blackburn S; Mahajan P; Boklage SH
    Rheumatol Ther; 2020 Sep; 7(3):517-535. PubMed ID: 32440826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians.
    Sullivan E; Kershaw J; Blackburn S; Choi J; Curtis JR; Boklage S
    Rheumatol Ther; 2020 Jun; 7(2):383-400. PubMed ID: 32318979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
    Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
    BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.
    Lie E; van der Heijde D; Uhlig T; Mikkelsen K; Rødevand E; Koldingsnes W; Kaufmann C; Kvien TK
    Ann Rheum Dis; 2011 Jan; 70(1):157-63. PubMed ID: 21062852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.
    Kvamme MK; Lie E; Uhlig T; Moger TA; Kvien TK; Kristiansen IS
    Rheumatology (Oxford); 2015 Jul; 54(7):1226-35. PubMed ID: 25573840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kalstad S; Rødevand E; Mikkelsen K; Lexberg AS; Kvien TK
    Ann Rheum Dis; 2013 Nov; 72(11):1840-4. PubMed ID: 23562987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
    Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
    Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis.
    Song Y; Betts KA; Lu Y; Singh R; Clewell J; Griffith J
    Rheumatol Ther; 2019 Jun; 6(2):285-297. PubMed ID: 31055779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.